Cancer Genetics Inc (NASDAQ:CGIX) traded down 10% during trading on Monday . The stock traded as low as $0.09 and last traded at $0.09, 1,016,645 shares changed hands during mid-day trading. A decline of 51% from the average session volume of 2,079,242 shares. The stock had previously closed at $0.10.

The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 0.04. The firm’s 50-day simple moving average is $0.11 and its 200 day simple moving average is $0.19.

Cancer Genetics (NASDAQ:CGIX) last posted its earnings results on Monday, August 19th. The medical research company reported ($0.01) EPS for the quarter. Cancer Genetics had a negative return on equity of 208.35% and a negative net margin of 98.13%. The firm had revenue of $1.53 million during the quarter.

An institutional investor recently raised its position in Cancer Genetics stock. Renaissance Technologies LLC grew its position in Cancer Genetics Inc (NASDAQ:CGIX) by 38.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,777,125 shares of the medical research company’s stock after purchasing an additional 769,896 shares during the period. Renaissance Technologies LLC owned approximately 4.80% of Cancer Genetics worth $453,000 as of its most recent SEC filing. 11.21% of the stock is owned by institutional investors.

Cancer Genetics Company Profile (NASDAQ:CGIX)

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

See Also: P/E Growth (PEG)

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.